Abstract

Hemoptysis, the expectoration of blood arising from the lower respiratory tract, is commonly seen with primary intrathoracic malignancies and is less frequently due to metastatic disease such as differentiated thyroid carcinoma (DTC). Nonetheless, patients with DTC who develop hemoptysis require careful assessment to determine whether metastatic DTC is involving either the central airways or the lung parenchyma, as well as to consider whether the bleeding is due to a broad range of other neoplastic, infectious, or inflammatory disorders. Bronchoscopy may be required to localize the source of bleeding, and tissue acquisition to confirm a histologic diagnosis is often appropriate when there is clinical uncertainty as to the etiology. Once metastatic DTC is identified as the cause, hemoptysis can be managed with a variety of localized interventions, including bronchoscopic coagulation and resection, surgical resection, or radiotherapy. The absence of prospective comparative trials among the various treatment modalities or of data specific to DTC leads to reliance upon retrospective analyses and local physician biases for therapy selection.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.